Next Science Ltd (ASX: NXS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Next Science Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $244.50 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 197.97 million
Earnings per share -0.048
Dividend per share N/A
Year To Date Return -2.00%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Next Science Ltd (ASX: NXS)
Latest News

NXS ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Next Science Ltd

Next Science Ltd is a medical technology company. The company is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria.

NXS Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
25 Oct 2021 $1.22 $-0.01 -0.82% 19,241 $1.22 $1.24 $1.22
22 Oct 2021 $1.23 $0.01 0.82% 21,746 $1.22 $1.28 $1.22
21 Oct 2021 $1.22 $-0.04 -3.17% 47,882 $1.26 $1.29 $1.22
20 Oct 2021 $1.26 $-0.03 -2.33% 47,017 $1.30 $1.30 $1.26
19 Oct 2021 $1.29 $-0.01 -0.77% 73,069 $1.30 $1.31 $1.27
18 Oct 2021 $1.31 $-0.03 -2.26% 44,559 $1.32 $1.32 $1.30
15 Oct 2021 $1.33 $0.11 8.98% 124,916 $1.25 $1.33 $1.22
14 Oct 2021 $1.23 $0.03 2.50% 64,447 $1.22 $1.24 $1.20
13 Oct 2021 $1.20 $0.00 0.00% 93,383 $1.20 $1.24 $1.20
12 Oct 2021 $1.20 $-0.03 -2.44% 139,111 $1.21 $1.23 $1.15
11 Oct 2021 $1.23 $-0.02 -1.60% 74,093 $1.25 $1.26 $1.21
08 Oct 2021 $1.25 $-0.01 -0.79% 72,688 $1.26 $1.26 $1.23
07 Oct 2021 $1.26 $0.02 1.61% 168,989 $1.24 $1.26 $1.21
06 Oct 2021 $1.24 $-0.05 -3.88% 127,565 $1.29 $1.29 $1.24
05 Oct 2021 $1.29 $0.02 1.57% 179,695 $1.27 $1.29 $1.25
04 Oct 2021 $1.27 $-0.03 -2.31% 43,894 $1.30 $1.30 $1.27
01 Oct 2021 $1.30 $-0.04 -2.99% 72,024 $1.34 $1.34 $1.30
30 Sep 2021 $1.34 $0.02 1.51% 141,259 $1.33 $1.34 $1.30
29 Sep 2021 $1.33 $0.02 1.53% 31,501 $1.31 $1.35 $1.31
28 Sep 2021 $1.31 $-0.04 -2.99% 27,995 $1.33 $1.34 $1.30

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
28 Apr 2021 Daniel (Dan) Spira Sell 3 $5,962
As advised by the company. Avg Price, Sale of shares to cover the balance of costs of exercising 1,040,000 US$0.42 options expiring 16 April 2021.
26 Apr 2021 Daniel (Dan) Spira Sell 362 $568,876
As advised by the company. Avg price.
Sale of shares to partially cover costs of
exercising 1,040,000 US$0.42 options
expiring 16 April 2021.
13 Apr 2021 Daniel (Dan) Spira Buy 1 $572,000
Exercise of options.
13 Apr 2021 Daniel (Dan) Spira Exercise 1 $572,000
Exercise of options.
24 Nov 2020 Bruce Hancox Buy 130 $149,344
On-market trade. Avg price.
24 Nov 2020 Judith Mitchell Buy 43 $49,020
On-market trade. As per announcement on 25/11/2020.
Avg price
24 Nov 2020 Judith Mitchell Buy 24 $27,772
On-market trade. As per announcement on 25/11/2020.
Avg price
29 Oct 2020 Judith Mitchell Buy 178 $205,755
On-market trade. Avg price.
29 Oct 2020 Judith Mitchell Buy 22 $25,907
On-market trade. Avg price.
28 Oct 2020 Bruce Hancox Buy 30 $34,800
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Mark Raymond Compton Non-Executive DirectorNon-Executive Chairman Oct 2018
Mr Compton is Lord Prior of the International Order of St John and Chairman of the Board of Trustees of St John International. He is also Chairman of St Luke's Care Limited and Chairman of Integrated Clinical Oncology Network Pty Ltd trading as Icon Cancer Centre. Mark has held range of CEO and managing director roles, including at St Luke's Care Limited, Immune System Therapeutics Limited, Royal Flying Doctor Service of Australia, SciGen Limited and Alpha Healthcare Limited. He is an Adjunct Professor at Macquarie University in healthcare leadership and management (since 2012). He is a member of People, Culture Committee.
Mr Bruce Alan Hancox Non-Executive Director Oct 2017
Mr Hancox has over 35 years of corporate experience across commerce, including 16 years with Brierley Investments Limited in New Zealand. He held a number of senior roles at Brierley Investments as general manager and Chairman and served on the board of a number of their subsidiaries in New Zealand, Australia and the US. Bruce has been a financial advisor to interests of Mr Langley Walker since 2008. He serves as a director of investments and wealth management at Walker Corporation Pty Ltd and works with the Walker group of companies to pursue investment opportunities outside the property market. He is a Director of Walker Group Holdings Pty Limited. He is Chair of the Risk Committee.
Mr Daniel (Dan) Spira Non-Executive Director Oct 2017
Mr Spira is the CEO of iNova Pharmaceuticals (since 2017) which is a multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously he was at Bausch Health (2011-2015) as Vice President and GM North America and was also Managing Director, Pacific region. Prior to that, Daniel spent over 15 years at Johnson & Johnson Inc in range of roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions. He is a Chair of People, Culture Committee.
Mrs Aileen Stockburger Non-Executive Director Oct 2018
Mrs Stockburger was the Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. She led Johnson & Johnson's efforts to acquire Synthes. She also led the efforts to divest the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also part of range of other M&A transactions including Pfizer Consumer Healthcare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. He is a Non-Executive Director of Microbot Medical Inc. She is a member of Risk Committee.
Ms Judith Mitchell Managing Director Oct 2017
Ms Mitchell served as President of DePuy Synthes Asia Pacific, the Orthopaedics Division of Johnson & Johnson, before which Judith was President of Asia Pacific for Synthes GmbH. Judith commenced her medical technology career at GE Medical Systems, where over 14 years, she held positions in sales, marketing and management. She also held a range of positions at Cochlear Limited in Product Development, Global Marketing and Education.
Ms Gillian Maria Nairn Company Secretary Jun 2018
-
Dustin Haines Chief Commercial Officer
-
Jacqueline Butler Chief Financial Officer
-
Jon Swanson Chief Operating Officer
-
Matthew Myntti Chief Technology Officer
-
Gillian Maria Nairn Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Auckland Trust Company Ltd ATF Secord Pacific Master Superannuation Fund 56,019,938 28.85%
Walker Group Holdings Pty Limited 21,719,667 11.18%
Matthew Myntti 20,657,000 10.64%
HSBC Custody Nominees (Australia) Limited A/C 2 6,299,588 3.24%
Merrill Lynch (Australia) Nominees Pty Limited 5,130,056 2.64%
Judith Mitchell 4,744,438 2.44%
HSBC Custody Nominees (Australia) Limited 3,534,393 1.82%
UBS Nominees Pty Ltd 3,464,130 1.78%
Mr Charles Robert Dirck Wittenoom 2,825,000 1.45%
National Nominees Limited 2,443,875 1.26%
Citicorp Nominees Ply Limited 1,637,135 0.84%
Scone Investments Pty Ltd 1,159,452 0.60%
G & N Lord Superannuation Pty Ltd <GNR Superannuation Fund A/C> 965,000 0.50%
Mr Byron James Darroch 962,500 0.50%
Ka-tet Pty Ltd <The Rosenrot Trust> 890,500 0.46%
Donald Ayers 672,394 0.35%
Insync Investments Pty Ltd <Weekley Super Fund No 1 A/C> 625,000 0.32%
Authentics Australia Pty Ltd <Authentics Australia A/C> 512,438 0.26%
Tsunami Ventures Pty Ltd <Drizzle Family A/C> 500,938 0.26%
Honne Investments Pty Limited 500,000 0.26%

Profile

since

Note